Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of MLN0264 in Previously Treated Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Expressing Guanylyl Cyclase C (GCC)

NCT02202785 is registered in ClinicalTrials.gov with Millennium Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02202785
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02202785 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of MLN0264 in Previously Treated Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Expressing Guanylyl Cyclase C (GCC)
Lead sponsor
Millennium Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
July 2, 2014
Completion date
January 15, 2016
Enrollment
43 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic adenocarcinoma